Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer

Completed · Phase 1/Phase 2

Conditions studied: Breast Cancer, Ovarian Cancer

In brief

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells. It is not yet known whether combining vaccine therapy with interleukin-2 is effective in treating breast and ovarian cancer. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and interleukin-2 and to see how well they work in treating women with stage IV, recurrent, or progressive breast or ovarian cancer.

Key facts

Study ID

NCT00019916

Run by

National Cancer Institute (NCI)

Starts

2000-06-01

Expected to finish

2006-07-01

Last updated by the study team

2013-06-20

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• NCI - Center for Cancer Research — Bethesda, Maryland, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.